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Abstract The burden of community-acquired pneumonia
(CAP) in high-income countries is still significant. The intro-
duction of pneumococcal conjugate vaccines (PCV) has re-
duced the overall need for hospitalization for CAP. However,
it is not clear whether children with underlying disease also
have benefitted from the PCV immunization programme.
Children 0 to <5 years of age hospitalized with CAP and
discharged with an ICD-10 code of J13-J18.9 between
November 1, 2005, and April 30, 2007 (pre-vaccination peri-
od), and November 1, 2010, and April 30, 2012 (post-vacci-
nation period), were eligible for this study. Data on hospitalization
and discharge diagnoses were retrieved from the Hospital
Registry. In addition, chart review was performed in 50% of the
patients. Our result confirmed a decrease in hospitalization rate for
CAP in the PCV13 period. Chart review revealed that half of the
patients had underlying comorbidity and these children had more
severe symptoms and required longer hospital stay. Intensive care
was provided to less than 10% of the children and mostly for
children with an underlying neurological disease.
Conclusions: We show that all children have benefitted
from the reduction of CAP hospitalization after introduction
of PCV. Our finding emphasizes the importance of children
with chronic diseases receiving adequate vaccinations that
may protect from lower respiratory diseases.
What is known?
• Community-acquired pneumonia is a leading infectious cause of
hospitalizations and death among children <5 years of age globally
• Pneumococcal conjugate vaccine reduces the hospitalizations of
all-cause pneumonia
What is new?
• We show that also children with underlying comorbidities have
benefitted from PCV immunization with a reduction of CAP
hospitalization
• We show that approximately half of all children hospitalized with CAP
also have underlying comorbidities.
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Introduction
Community-acquired pneumonia (CAP) is a leading infec-
tious cause of hospitalizations and death among children
<5 years of age globally [2, 13]. Among the estimated in-
hospital deaths, the majority (99%) occur in low-income
countries. Although the disease burden from childhood pneu-
monia is lower in high-income countries, medical service uti-
lization, emergency visits and antibiotic use and related costs
remain substantial. Despite this, there are relatively few stud-
ies related to the clinical burden in hospitalized children with
pneumonia in high-income countries [12].
Major pathogens associated with childhood CAP include
Streptococcus pneumonia, Haemophilus influenzae,
Staphylococcus aureus, Chlamydophila pneumoniae and
Mycoplasma pneumoniae [14, 21]. A number of viral patho-
gens including respiratory syncytial virus, rhinoviruses, hu-
man metapneumoviruses, adenoviruses and influenza have
been acknowledged as important pathogens for CAP as well
[8, 13]. However, identifying the cause of paediatric CAP has
been problematic due to poor sensitivity of conventional mi-
crobial tests, such as blood cultures and nasopharyngeal (NP)
cultures, to accurately identify bacteria involved in the local-
ized lung infection. Molecular methods for identification of
both viruses and bacteria may improve sensitivity, but perhaps
not accurately predict viral vs. bacterial origin of CAP, since it
has been increasingly recognised that healthy children may
also be carriers of viruses in NP samples [16, 19]. The intro-
duction of both H. influenzae type b and more recently pneu-
mococcal conjugate vaccines (PCV) has had a great impact on
CAP hospitalizations and mortality in both low- and high-
income countries [5, 10, 11]. Pneumococcal conjugate vac-
cine PCV7, as the most studied vaccine so far, has repeatedly
been reported to reduce hospitalizations due to pneumonia,
which in most studies is defined as radiologically confirmed
pneumonia, bacterial and non-bacterial pneumonia or cases
identified through ICD codes. The range of reduction of all-
cause pneumonia has been reported between 13 and 65% in
countries as Italy, Poland, the US and Sweden after the intro-
duction of PCV [1, 5, 10, 18].
However, there are still some unresolved problems related
to the prevention and management of paediatric CAP in high-
income countries. Hospitalization of children with CAP is
already recommended for moderate-severe pneumonia, chil-
dren with unstable vital parameters and in children with co-
morbidities. The most common comorbidities associated with
CAP and/or invasive pneumococcal disease (IPD) are
immunodeficiency, any type of childhood cancer, congenital
heart or lung disease and neurological diseases [7, 8, 15].
Despite this, little data is available on the burden of CAP in
children with comorbidities based on population data.
In Stockholm County, Sweden, PCV7 was offered on a 2 +
1 schedule at 3, 5 and 12 months of age to all children born
since July 1, 2007. In January 2010, PCV7 was changed to
PCV13 even for children who had received 1 or 2 doses of
PCV7. No catch-up programme was implemented. High vac-
cine coverage was reached early on, and 98% of children born
2010 had received 3 doses of PCV [10]. Using a population-
based retrospective cohort of children residing in Stockholm
County, we sought to describe underlying comorbidities in
children less than 5 years of age, hospitalized with CAP before
and after the introduction of PCV. In addition, we provide data




Data for this retrospective cohort study were retrieved from
the Hospital Registry, which contains information on hospi-
talization and discharge diagnoses covering all paediatric ad-
missions in the Stockholm County. The three paediatric hos-
pitals located in Stockholm participated in the study, all with
paediatric emergency departments and one serving as a refer-
ral centre for ICU cases for children from the Stockholm
County, Sweden. Incidence of pneumonia was calculated with
population data from the Regional Planning Office,
Stockholm County Council for the respective time periods.
The population of children <18 years increased from
416,000 in the pre-vaccination period to 451,000 in the post-
vaccination period. In addition, to validate diagnoses and re-
trieve in-depth data on comorbidity, 50% of all medical re-
cords were reviewed. The Regional Ethical Board in
Stockholm, Sweden, approved of the study (D-no.: 2011/44-
31/1).
Patients
Children aged 0 to <5 years hospitalized for CAP were eligi-
ble for this study if they were residing in Stockholm county,
discharged from the three participating hospitals between
November 1, 2005 and April 30, 2007 (pre-vaccination
period) and November 1, 2010 and April 30, 2012 (post-vac-
cination period). Subjects living in the Stockholm area were
included if they were discharged with an ICD-10 code of J13-
J18.9 which excludes a diagnosis of pneumonia of known
viral origin. A readmission occurring within 30 days from first
admission/discharge was checked through chart revision and
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excluded if considered a deterioration of the first episode. In
the post-vaccination period, the vaccine up-take was estimated
to 80% in our cohort based on the age of the child at admission
in relation to the three-dose vaccine schedule. In children aged
2 to >5 years, 34 children (5.7%)were born before July 1 2007
and thus not offered PCV7.
Study definitions
Patients with chronic comorbid conditions were identified
through their respective discharge diagnosis and through chart
review. The underlying diseases within each risk group in this
study are shown in Table 1. During chart review, the CAP
cases were further classified as severe using a previously pub-
lished classification scheme [4]. For the pneumonia to be clas-
sified as severe, the child had to have ≥1 major criteria; need
of mechanical ventilation, acute need of non-invasive positive
pressure ventilation, hypoxemia (less than SpO2 below 90%)
or >2 minor criteria; tachypnea greater than age-adjusted re-
spiratory rates, apnoea, increased breathing work, altered
mental status or unexplained metabolic acidosis [4].
Statistics
Statistical analysis was done in SPSS 21.0 and Stata/IC 12.0.
Fischer’s exact test and Chi square statistics were used to
compare parameters in the pre- and post-period and to com-
pare parameters between the children with and without risk
factors.We stratified the subjects in two age groups (0< 2 years
of age, 2 to <5 years of age). Mann-Whitney tests were per-
formed to compare median and mean values. A p value of
<0.05 was considered significant.
Results
Cohort characteristics and total incidence of CAP
hospitalizations
Patients hospitalized due to CAP are described in Table 2 for
the two study periods. As expected, children <2 years of age
accounted for approximately 60% of the hospitalized cohort in
both time periods. The incidence of hospitalizations with
pneumonia coded as bacterial was compared for the two pe-
riods. In children <2 years of age, the yearly incidence de-
creased from 5.1 (95% CI: 4.6–5.5) to 3.4 (3.1–3.7)/1000
children. In the older age group of 2- to <5-year-old children,
a minor reduction was noticed from 2.5 (2.3–2.8)/1000 to 2.0
(1.8–2.3)/1000 children.
Severity of pneumonia, complications and mortality
in the selected study population
For further understanding of the importance of comorbidities
for hospitalization of children with CAP, patients (n = 621)
were randomly selected for chart review (Table 3). This cohort
was similar with respect to gender and age groups compared
to all hospitalized CAP children (n = 1332), but the proportion
of children with comorbidities was higher in the patient cohort
where chart review was performed compared to data based on
discharge diagnosis only (50 vs. 30%). Clinical parameters
indicating severity of pneumonia were compared in children
with or without risk factors (Table 3) for each study period.
Children with comorbidity were classified with more severe
pneumonia and were also cared for in the PICU more often.
PICU care was in the majority of cases provided for children
<2 years of age (data not shown). Complications to CAP were
rare, but there were two children in the pre-immunization pe-
riod and 6 children in the post-immunization period that suf-
fered from a complication represented by 5 cases of empyema,
Table 1 Definitions of chronic comorbidity used in this study and their
prevalence in the chart review (n = 621) conducted from the two time
periods











































a Chronic morbidities accounting for less than 5% in the cohort were
grouped together as ‘other risk factors
Table 2 Patient characteristic in the total cohort (n = 1332) based on
ICD discharge diagnosis
Pre-period Post-period
Total cohort 739 593
Gender M (%) 350 (43) 329 (55)
Age group <2 years (% ) 438 (59) 337 (57)
Age group 2 to <5 years (%) 301 (41) 256 (43)
Children with comorbidities (%) 210 (28) 197 (33)
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one case of lung abscess, necrotizing pneumonia and
septicaemia, respectively. In five children <2 years of age with
severe underlying neurological disease, CAPwas contributing
to in-hospital death as revealed by chart review. Two of these
children were born before the PCV introduction and where
thus not offered PCV vaccination. Interestingly, when com-
paring the study cohort over the two periods, there were sig-
nificantly more cases classified as severe pneumonia in the
post-period (p = 0.035) (data not shown). We also recorded
the length-of-stay (LOS) for the two study periods as it may
correlate to severity and underlying comorbidity. In the pre-
period, the median LOS was 2 days for all children under the
age of 5, and this increased to 3 days in the post-period
(p = 0.027). Children with comorbidities stayed significantly
longer in the hospital than did children without previous ill-
nesses (p = 0.000) during the whole period, including pre- and
post-period (data not shown).
Characteristics in children with comorbidities
The majority of children with comorbidity (n = 209, 63.1%)
had only one underlying disease. However, 91 children
(27.5%) had two comorbidities and 31 children (9.4%) had
three or more comorbidities. The most common risk factor in
both age groups and both periods was obstructive disease
requiring regular medication present in approximately half
of the patients with comorbidity (Table 1). The effect of im-
munization on the number of children with comorbidities was
most evident in the younger age group. In the post-
immunization period, the risk groups including children with
chronic lung disease or heart disease, congenital
malformations/syndrome and other risk factors decreased in
number, but not in proportion of the total number of cases.
Among children that required PICU care, the most common
risk factors were neurological disease followed by obstructive
disease (Fig. 1). Comparing the two periods, an increase in the
number of children with neurological disease requiring PICU
care was noticed in the post-immunization period.
Discussion
In this retrospective study, children admitted to hospital for
pneumonia have been characterized with respect to comorbid-
ities and severity of disease before and after the introduction of
a PCV into the Swedish childhood immunization programme.
We conclude that children with underlying comorbidities also
have benefitted from the introduction of PCV similar to oth-
erwise healthy children.
Since the introduction of PCV in Sweden, the incidence of
pneumonia hospitalizations in children <5 years of age has
decreased as previously reported by us and others [10, 1]
and is in accordance to several international studies [3, 5,
12]. The study by Berglund et al. covered several parts of
Sweden with slightly different vaccine strategies from 2010
and onwards. In our cohort, the largest effect was seen in
children <2 years of age, and these young children <2 years
had received PCV7 or PCV13 (introduced in Jan. 2010). On
the other hand, some children 3–5 years of age in the older age
group may not have been offered PCV at all. It is therefore
likely that the positive vaccine effect may increase also in the
older age group in the coming years when all children have
been offered PCV13. Although the trend of a reduced hospi-
talizations rate is similar in our study compared to Berglund
et al., it should be noted that the patient cohorts differed as
children with viral pneumonia were excluded in our study.
Table 3 Hospitalization data extracted by chart review (n = 621) from







180 (53%) 157 (47%)
Post
n = 284
162 (57%) 122 (43%)
Age <2 years Pre
n = 204
103 (50.5) 101 (49.5)
Post
n = 146
77 (51,4%) 71 (48.6%)
Male gender Pre
n = 173
92 (53.7%) 81 (46.3%)
Post
n = 152












Fatal cases Pre 2 0
Post 3 0
a Significant increase in the post-immunization period (Fishers exact test)
Fig. 1 Underlying chronic conditions in children 0–4 years requiring
PICU care for pneumonia in pre- and post-period
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To understand whether PCV has benefitted children with un-
derlying diseases, we also registered comorbidities associated
with CAP hospitalization. Previous studies from the USA [7,
15] suggest that PCV has significantly lower efficacy in
preventing IPD in children with some comorbidities such as
immunodeficiency, chronic medical conditions and asthma com-
pared with children with no underlying disease. However, our
results suggest that children with comorbidities also benefit from
the PCV vaccination since the proportion of children with co-
morbidities and pneumonia was similar before and after the uni-
versal introduction of PCV. In addition, it is also important to also
stress that the actual number of children with comorbidities de-
creased in after the introduction of PCV and this was most evi-
dent for children with congenital heart disease/malformations/
cancer and primary immunodeficiencies. However, one major
difference between previous studies and ours is that our study
was based on a discharge diagnosis of pneumonia coded as bac-
terial (J13-J18.9) and not based on culture-verified IPD. Our
finding emphasizes the importance of a high vaccine coverage
also in children with chronic diseases.
We next sought to elucidate whether the clinical course during
hospitalization differed in children with comorbidities compared
to otherwise healthy children. Chart review identified a higher
proportion of children with comorbidities than the coded dis-
charge diagnosis which emphasize the risk of only using ICD
codes. Different routine for coding between institutions aswell as
the accuracy of the individual paediatrician may impact studies
based on discharge diagnosis only. In our cohorts, obstructive
disease predominated in the two study periods as also shown in
two previous US studies [8, 15]. More than one underlying dis-
ease was present in one-third of the children with comorbidity. In
children <2 years of age, there were less children with congenital
malformations/syndromes or with other diseases (cancer, immu-
nosuppression, diabetes) in the post-immunization period. In the
older age group, the distribution of children with comorbidities
was rather similar.
Not surprisingly, children with comorbidities in our cohort
more often presented with severe pneumonia were more often
in need of PICU care. Unfortunately, it was not possible to as-
certain from the chart review whether the children with more
severe pneumonia actually had received PCVor not, which oth-
erwisewould have been interesting. The proportion of children in
PICU was much lower in our study compared to recently pub-
lished data from an active population-based surveillance study of
CAP in the USA [8]. Whether this reflects more severe or mul-
tiple comorbidities in the different populations or differences in
management of severe cases is difficult to ascertain. In the study
by Jain et al., 50% had underlying conditions, and 21% of ad-
mitted children were in need of ICU care although there may
have been a selection bias since one third of possible cases de-
clined participation. The frequency of direct complication to
pneumonia (empyema/sepsis) did not change significantly be-
tween the study periods in our population contrary to what has
been previously shown for empyema in the PCV post-
immunization era [6, 9]. Albeit it is possible that our cohort is
too small to detect any changes compared to the international
studies, themortality in our selected cohort was low and occurred
in children with underlying diseases, which is in accordance with
other studies [8, 12].
Several limitations exist with this study. Firstly, a limitation is
that the individual vaccination data were not available. However,
since data suggests a 98% high vaccine coverage for PCV in
children born 2010 in Stockholm county, we think that our esti-
mate of vaccine coverage based on age is reliable [10]. We can-
not exclude a selection bias for unvaccinated children with co-
morbidities, especially for the groups of children with perinatal
disease such as BPD or congenital malformations/syndromes
since these children may have received their immunizations later
in life compared to healthy newborns. However, these children
constituted a minor fraction of the children with comorbidities.
PCV also has a herd effect in non-vaccinated groups, and this
study was designed to evaluate the overall effect of the
programme.
Secondly, a limitation is that the initial selection of cases
has been made using ICD codes for pneumonia coded as bac-
terial and we know that there could be children who were
given the wrong diagnosis or where comorbidities were not
registered. However, to validate discharge diagnosis, we per-
formed chart review in a substantial number of cases.
Unfortunately, we could not establish the true aetiology of
pneumonia due to incomplete data during chart review, but
we know from other studies [8, 17] that all cases were not true
‘bacterial pneumonia . It was also evident that sampling for
microbiological diagnosis differed between the three hospitals
included. Within the same time frame as our study, viral PCR
diagnostics were introduced in 2007 [20], which may have
facilitated and correctly improved the diagnosis of viral pneu-
monia in children.
In conclusion, we show that all children have benefitted
from the reduction of CAP hospitalization after introduction
of PCV. In addition, we show that approximately half of all
children hospitalized with CAP also have underlying comor-
bidities. Our data suggests that studies only based on dis-
charge diagnosis may underestimate other important study
variables as in our case.
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